Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06962332 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)

StatusRecruiting
PhasePhase 1
SponsorExelixis
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 22, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 2 · Start date changed from estimate of May 2025 to May 13, 2025v2 Show 2 more changesShow less
    • Study sites: 0 to 2
    • Start date changed from estimate of May 2025 to May 13, 2025
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Exelixis
25 trials monitored
See 2 trials at risk
The primary purpose of this study is to evaluate the plasma PK of zanzalintinib following a single dose in participants with moderate liver dysfunction compared to matched healthy participants with normal liver function.
Trial Details
NCT Number NCT06962332
Lead Sponsor Exelixis
Conditions Hepatic Impairment, Moderate Hepatic Impairment
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov